Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Drugs Gain Status Boost Within CDER

This article was originally published in The Pink Sheet Daily

Executive Summary

More than just a bureaucratic shell game, the promotion of the Office of Generic Drugs to “super office” status signals CDER Director Janet Woodcock’s tightened focus on generic drugs.

Advertisement

Related Content

Gottlieb Promotes 'Team' Work For Product Reviews
CDER’s Drug Quality Office Separates Oversight Of ‘New’ And ‘Lifecycle’ Products
CDER’s Counter-Terrorism, Emergency Coordination Operations Get New Home
CDER’s Counter-Terrorism, Emergency Coordination Operations Get New Home
FDA Office Of Generic Drugs Director Has Brand Industry Background
FDA Drug Shortage Strategy: Enforcement Discretion, Patient Public Relations
FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion
FDA Reshuffles Office Of Generic Drugs To Improve Performance
FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
CDER’s Drug Integrity Program Gains Formal Role In Compliance Office Reorg

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel